<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2326">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04558476</url>
  </required_header>
  <id_info>
    <org_study_id>2020-003102-31</org_study_id>
    <nct_id>NCT04558476</nct_id>
  </id_info>
  <brief_title>Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation</brief_title>
  <acronym>CONFIDENT</acronym>
  <official_title>A Multicenter Randomized Trial to Assess the Efficacy of CONvalescent Plasma Therapy in Patients With Invasive COVID-19 and Acute Respiratory Failure Treated With Mechanical Ventilation: the CONFIDENT Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Liege</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KCE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Liege</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principal objective of the CONFIDENT trial is to assess the efficacy of two units
      (400-500 mL in total) of convalescent plasma, as compared to Standard of Care (SoC), to
      reduce day-28 mortality in patients with SARS-CoV-2 pneumonia who require mechanical
      ventilation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design : multicenter randomized openlabel, phase II trial.

      Number of patients to include : 500 (250 with plasma, 250 without plasma).

      The principal objective is to assess the efficacy of the treatment to reduce day-28 mortality
      in patients with SARS-CoV-2 pneumonia who require mechanical ventilation.

      Hypothesis: Passive immunization with plasma collected from patients having contracted
      COVID-19 and developed specific antibodies may alleviate symptoms and viral load of
      SARS-CoV-2 and reduce mortality.

      The patients will receive currently accepted standard of care for both COVID-19 and usual
      organ dysfunctions observed in such cases. half the patients will be administered either
      Convalescent plasma, depending on the randomization process. All patients will be followed-up
      for one year after inclusion. The study will be considered either positive or negative, based
      on the principal objective. This means that the product convalescent plasme will be
      considered effective if mortality at day 28 is lower is patients treated with convalescent
      plasma than without it. The follow-up will allow to assess a series of secondary objectives,
      addressing the evolution of organ failures, viral infection, inflammatory response and
      long-term physical of psychological impact of COVID-19. Interim analyses will be performed
      every 100 patients included in order to stop the trial if an exceptionally good or bad result
      is observed, to prevent using or not using the product appropriately in further patients.
      These analyses will be supervised by an independent committee.

      The choice to include only those patients under mechanical ventilation for severe respiratory
      failure makes this study different from other trials testing convalescent plasma, as most
      trial include less severe patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vital status</measure>
    <time_frame>at day 28</time_frame>
    <description>dead or alive</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>day 90 mortality</measure>
    <time_frame>at day 90</time_frame>
    <description>dead or alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of ventilator-free days at day 28</measure>
    <time_frame>at day 28</time_frame>
    <description>to assess the ventilator free days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of renal replacement therapy free days at day 28</measure>
    <time_frame>at day 28</time_frame>
    <description>to assess the number of renal replacement therapy free days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of vasopressors free-days at day 28</measure>
    <time_frame>at day 28</time_frame>
    <description>to assess the number of vasopressors free-days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>use of ECMO before day 28</measure>
    <time_frame>till day 28</time_frame>
    <description>to assess if ECMO was required</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>value of the SOFA score at days 7, 14 and 28</measure>
    <time_frame>Day 1, 7, 14, 28</time_frame>
    <description>to assess the value of SOFA score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in SOFA scores (delta SOFA) over 7, 14 and 28 days</measure>
    <time_frame>Day 7, 14 and 28 days</time_frame>
    <description>to assess the changes in SOFA scores (delta SOFA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment of the SARS-CoV-2 viral load</measure>
    <time_frame>Days 7, 14 and 28</time_frame>
    <description>assessment of the SARS-CoV-2 viral load, expressed as cycle threshold, [2] in the tracheal aspirates (for intubated patients) or nasopharyngeal swabs (for extubated patients) at days 7, 14 and 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood C reactive protein (CRP) concentration</measure>
    <time_frame>Days 7, 14 and 28</time_frame>
    <description>to assess the concentrations of C reactive protein (CRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ferritin concentration</measure>
    <time_frame>Days 7, 14 and 28</time_frame>
    <description>to assess the concentration of ferritin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lymphocyte count</measure>
    <time_frame>Days 7, 14 and 28</time_frame>
    <description>to assess the count of lymphocyte</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of stay in the acute care hospital</measure>
    <time_frame>through study completion, 1 year</time_frame>
    <description>to assess the lenght of stay in the acute care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>location of the patient</measure>
    <time_frame>Day 90</time_frame>
    <description>to assess the location of the patient : acute care hospital, post acute care hospital, long-term residency, home</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Katz Index of independence in Activity Day Living functional score</measure>
    <time_frame>Day 90 and 365</time_frame>
    <description>to assess the Activity Day Living functional Min value: 0 = Low (patient very dependent) Max value: 6 = High (patient independent)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>Day 90 and 365</time_frame>
    <description>to evaluate the anxiety-depression For each item 0-7 : Normal 8-10 : Bordeline abnormal (borderline case) 11-21 : Abnormal case</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life scale EQ-5D-5L</measure>
    <time_frame>Day 90 and 365</time_frame>
    <description>The EQ-5D-5L is composed of - the EQ-5D-5L descriptive system and the EQ Visual Analogue scale (EQ VAS). The descriptive system comprises 5 dimensions (mobility, self care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Each level corresponds to 1-digit number expressing the level selected for that dimension.
The EQ VAS corresponds to a 20 cm vertical, visual analogue scale raging from 'the best health you can imagine' to 'the worst health you can imagine'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion related adverse events</measure>
    <time_frame>till 28 days</time_frame>
    <description>to assess the transfusion related adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Covid19</condition>
  <condition>Mechanical Ventilation Complication</condition>
  <condition>Corona Virus Infection</condition>
  <condition>Respiratory Failure</condition>
  <condition>SARS (Severe Acute Respiratory Syndrome)</condition>
  <arm_group>
    <arm_group_label>Convalescent Plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 units of plasma ( 400-500ml) from 2 different donnors duration of treatment =2 h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard of care according the last gold standards</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Convalescent Plasma</intervention_name>
    <description>2 units of convalescent plasma</description>
    <arm_group_label>Convalescent Plasma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Gold Standards</description>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age at least 18 years

          -  hospitalization in an intensive care unit participating to the study

          -  medical diagnosis with SARS-CoV-2 pneumonia as defined by both:

               -  extended interstitial pneumonia on CT scan or a chest X-ray, consistent with
                  viral pneumonia, within 10 days prior to inclusion

               -  Positive result of SARS-CoV-2 PCR test, or any emerging and validated diagnostic
                  laboratory test for COVID-19, within 15 days prior to inclusion

          -  under mechanical ventilation administered through an endotracheal tube, for less than
             5 days

          -  prior Clinical Frailty Scale &lt; 6.

          -  written consent of the patient, or - if impossible - of a relative acting as the legal
             representative, or - if impossible - of a physician from a non-participating
             department of the same hospital acting as an impartial witness .

        Exclusion Criteria:

          -  Pregnancy

          -  Prior episode of transfusion-related side effect

          -  Medical decision to limit therapy

          -  Current participation in another trial testing a COVID-19 therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Benoit Misset, MD,PhD</last_name>
    <phone>003243667495</phone>
    <email>benoit.misset@chuliege.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Axelle Bertand</last_name>
    <phone>003242843975</phone>
    <email>Axelle.Bertrand@chuliege.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>OLVZ Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie De Mey, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Antwerp</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Jorens, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imelda ZH Bonheiden</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel Van Der Hauwaert, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan Brugge</name>
      <address>
        <city>Bruges</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefaan Vandecasteele, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Saint Pierre</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane De Wit, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Grimaldi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth De Waele, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Charleroi Marie Curie</name>
      <address>
        <city>Charleroi</city>
        <zip>6042</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michaël Piagnerelli, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Sint Blasius</name>
      <address>
        <city>Dendermonde</city>
        <zip>9200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter Swinnen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Hoste, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Groeningen Kortrijck</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stoffel Lamote, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHR Citadelle</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Fraipont, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoît Misset, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UC Louvain</name>
      <address>
        <city>Louvain</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre François Laterre, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Delta</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Dumoulin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU UCL Namur-Godinne</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Michaux, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 14, 2020</study_first_submitted>
  <study_first_submitted_qc>September 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2020</study_first_posted>
  <last_update_submitted>September 21, 2020</last_update_submitted>
  <last_update_submitted_qc>September 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Liege</investigator_affiliation>
    <investigator_full_name>Misset Benoit</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Covid 19</keyword>
  <keyword>Convalescent plasmatherapy</keyword>
  <keyword>SARS Cov-2 pneumonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

